The US Food and Drug Administration (FDA) has approved MSD’s KEYTRUDA regimen as a first-line treatment for adults with unresectable advanced or metastatic malignant pleural mesothelioma (MPM). An anti-programmed death receptor-1 (PD-1) therapy, the treatment is indicated for use in combination with pemetrexed and platinum chemotherapy. The gold standard of business intelligence.
The approval for the KEYTRUDA regimen is supported by the results from the Phase II/III IND.227/KEYNOTE-483 clinical trial. The study was a collaborative effort involving CCTG, Intergroupe Francophone de Cancérologie Thoracique and the National Cancer Institute of Naples.
MSD provided both the medication and additional support for the trial. The Phase III segment of the IND.227/KEYNOTE-483 trial enrolled 440 patients who had not received prior systemic therapy for their advanced MPM.
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Your download email will arrive shortly We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form Participants were randomly assigned to receive either KEYTRUDA with chemotherapy or chemotherapy alone, with all treatments administered via intravenous infusion. The combination led to a statistically significant improvement in ov.